Recent Company News

• 08:08 AM ET Apr 28, 2025
  

  Chemomab reports new clinical data on nebokitug in primary sclerosing cholangitis and related diseases at EASL 2025 ($1.31, 0.00)

• 08:06 AM ET Apr 15, 2025
  

  Chemomab Therapeutics appoints David Weiner as Interim Chief Medical Officer, Jack Lawler as Chief Development Officer ($1.18, 0.00)

• 09:16 AM ET Mar 27, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:32 AM ET Mar 27, 2025
  

  Chemomab Therapeutics announces results from the Open Label Extension (OLE) portion of the Phase 2 SPRING trial ($1.16, 0.00)

• 08:12 AM ET Mar 06, 2025
  

  Chemomab Therapeutics announces presentation of nebokitug data ($1.40, 0.00)

• 08:10 AM ET Mar 03, 2025
  

  Chemomab Therapeutics reports Q4 EPS ($0.01) vs FactSet ($0.06) [3 est, ($0.15)-(0.01)] ($1.68, 0.00)

• 07:10 AM ET Feb 19, 2025
  

  Chemomab provides update on end-of-Phase 2 meeting with FDA for potential regulatory approval for nebokitug (CM-101) in primary sclerosing cholangitis ($1.93, 0.00)

• 07:09 AM ET Nov 19, 2024
  

  Chemomab Therapeutics announces presentations of data from SPRING trial of CM-101 at AASLD The Liver Meeting ($1.65, 0.00)

• 07:03 AM ET Nov 14, 2024
  

  Chemomab Therapeutics reports Q3 EPS ($0.01) vs FactSet ($0.06) [3 est, ($0.15)-(0.01)] ($1.74, 0.00)

• 01:13 PM ET Sep 20, 2024
  

  StreetAccount Activist Summary: Week of 16-Sep